Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.
2.

Efficacy of botulinum toxin in modifying spasticity to improve walking and quality of life in post-stroke lower limb spasticity - a randomized double-blind placebo controlled study.

Datta Gupta A, Visvanathan R, Cameron I, Koblar SA, Howell S, Wilson D.

BMC Neurol. 2019 May 11;19(1):96. doi: 10.1186/s12883-019-1325-3.

3.

Interstitial cystitis - intravesical treatment.

Almeida FG, Batezini NSDS, Simões RS, Bernardo WM.

Rev Assoc Med Bras (1992). 2019 May 2;65(4):535-540. doi: 10.1590/1806-9282.65.4.535.

4.

OnabotulinumtoxinA for Treatment of Forehead and Glabellar Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Double-Blind Study.

Ogilvie P, Rivkin AZ, Dayan S, Yoelin SG, Weichman BM, Garcia JK.

Dermatol Surg. 2019 May;45(5):689-699. doi: 10.1097/DSS.0000000000001779.

PMID:
31034447
5.

Functional Popliteal Artery Entrapment Syndrome: A Review of Diagnosis and Management.

Shahi N, Arosemena M, Kwon J, Abai B, Salvatore D, DiMuzio P.

Ann Vasc Surg. 2019 Aug;59:259-267. doi: 10.1016/j.avsg.2018.12.105. Epub 2019 Apr 24. Review.

PMID:
31028851
6.

Intra-articular botulinum toxin type A for treatment of knee osteoarthritis: Clinical trial.

Najafi S, Sanati E, Khademi M, Abdorrazaghi F, Mofrad RK, Rezasoltani Z.

Toxicon. 2019 Jul;165:69-77. doi: 10.1016/j.toxicon.2019.04.003. Epub 2019 Apr 14.

PMID:
30995453
7.

Botulinum Toxin Injections for Masseter Reduction in East Asians.

Cheng J, Hsu SH, McGee JS.

Dermatol Surg. 2019 Apr;45(4):566-572. doi: 10.1097/DSS.0000000000001859. Review.

PMID:
30883483
8.

Modified Selective Neurectomy for the Treatment of Post-Facial Paralysis Synkinesis.

Azizzadeh B, Irvine LE, Diels J, Slattery WH, Massry GG, Larian B, Riedler KL, Peng GL.

Plast Reconstr Surg. 2019 May;143(5):1483-1496. doi: 10.1097/PRS.0000000000005590.

PMID:
30807497
9.

Comparison between intra-articular Botulinum toxin type A, corticosteroid, and saline in knee osteoarthritis: a randomized controlled trial.

Mendes JG, Natour J, Nunes-Tamashiro JC, Toffolo SR, Rosenfeld A, Furtado RNV.

Clin Rehabil. 2019 Jun;33(6):1015-1026. doi: 10.1177/0269215519827996. Epub 2019 Feb 19.

PMID:
30782000
10.

How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxinA.

Przydacz M, Golabek T, Chlosta P.

Adv Clin Exp Med. 2019 Apr;28(4):555-567. doi: 10.17219/acem/90764. Review.

11.

Do Patients Discontinue Overactive Bladder Medications after Sacral Neuromodulation?

Amin K, Moskowitz D, Kobashi KC, Lee UJ, Lucioni A.

J Urol. 2019 May;201(5):973-978. doi: 10.1097/JU.0000000000000035.

PMID:
30694936
12.

Meta-analysis of clinical outcome after treatment for achalasia based on manometric subtypes.

Andolfi C, Fisichella PM.

Br J Surg. 2019 Mar;106(4):332-341. doi: 10.1002/bjs.11049. Epub 2019 Jan 28.

PMID:
30690706
13.

The Use of Botulinum Toxin Type A in the Healing of Thyroidectomy Wounds: A Randomized, Prospective, Placebo-Controlled Study.

Phillips TJ, Fung E, Rigby MH, Burke E, Hart RD, Trites JRB, Gassner HG, Taylor SM.

Plast Reconstr Surg. 2019 Feb;143(2):375e-381e. doi: 10.1097/PRS.0000000000005264.

PMID:
30688903
14.

IncobotulinumtoxinA: A Highly Purified and Precisely Manufactured Botulinum Neurotoxin Type A

Kerscher M, Wanitphakdeedecha R, Trindade de Almeida A, Maas C, Frevert J.

J Drugs Dermatol. 2019 Jan 1;18(1):52-57. Review.

PMID:
30681794
15.

Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke.

Santamato A, Cinone N, Panza F, Letizia S, Santoro L, Lozupone M, Daniele A, Picelli A, Baricich A, Intiso D, Ranieri M.

Drugs. 2019 Feb;79(2):143-160. doi: 10.1007/s40265-018-1042-z. Review.

PMID:
30623347
16.

Treatment of Keloid Scars with Botulinum Toxin Type A versus Triamcinolone in an Athymic Nude Mouse Model.

Fanous A, Bezdjian A, Caglar D, Mlynarek A, Fanous N, Lenhart SF, Daniel SJ.

Plast Reconstr Surg. 2019 Mar;143(3):760-767. doi: 10.1097/PRS.0000000000005323.

PMID:
30601323
17.

Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraine.

Bruloy E, Sinna R, Grolleau JL, Bout-Roumazeilles A, Berard E, Chaput B.

Plast Reconstr Surg. 2019 Jan;143(1):239-250. doi: 10.1097/PRS.0000000000005111.

PMID:
30589800
18.

Value of Urinary Brain-Derived Neurotrophic Factor Levels on the Assessment of Botulinum Toxin Type A Treatment for Neurogenic Detrusor Overactivity in Children with Myelodysplasia.

Sekerci CA, Tanidir Y, Toprak T, Basok BI, Isman F, Simsek F, Akbal C, Tarcan T.

J Urol. 2019 Jan;201(1):174-180. doi: 10.1016/j.juro.2018.06.065.

PMID:
30577408
19.

Effects of botulinum toxin type A on the treatment of dry eye disease and tear cytokines.

Choi MG, Yeo JH, Kang JW, Chun YS, Lee JK, Kim JC.

Graefes Arch Clin Exp Ophthalmol. 2019 Feb;257(2):331-338. doi: 10.1007/s00417-018-4194-3. Epub 2018 Dec 14.

PMID:
30552510
20.

Botulinum toxin type A for the treatment and prevention of hypertrophic scars and keloids: Updated review.

Kasyanju Carrero LM, Ma WW, Liu HF, Yin XF, Zhou BR.

J Cosmet Dermatol. 2019 Feb;18(1):10-15. doi: 10.1111/jocd.12828. Epub 2018 Dec 12. Review.

PMID:
30548742

Supplemental Content

Loading ...
Support Center